新药周观点：24Q2创新药板块持仓环比基本持平

Investment Rating - The report maintains an "Outperform" rating for the biotech sector, indicating a positive outlook compared to the broader market [5]. Core Insights - The biotech innovation sector saw a slight decrease in heavy holdings by all funds, with a total market value of 21.2 billion yuan in Q2 2024, down from 22 billion yuan in Q1 2024 [2][17]. - The proportion of heavy holdings in biotech innovation drugs relative to the overall market remained stable at 0.80%, while the proportion relative to the pharmaceutical industry increased to 8.02%, reflecting a growing preference for innovative drugs among institutions [2][20]. - The overall circulation market value of biotech innovation drugs is still seen as having significant room for growth, with heavy holdings accounting for only 3.70% of the total circulation market value [2][25]. Weekly New Drug Market Review - From July 15 to July 19, 2024, the top five companies in the new drug sector by stock price increase were: - Gilead Sciences (14.89%) - Kedi (8.13%) - Mengke Pharmaceutical (6.42%) - Keji Pharmaceutical (6.34%) - Shouyao Holdings (5.51%) - The top five companies by stock price decrease were: - Laika Pharmaceutical (-20.00%) - Hualing Pharmaceutical (-18.79%) - Lepu Biopharma (-15.85%) - Saintno Pharmaceutical (-12.62%) - Junsheng Tai (-12.22%) [1][11]. New Drug Approval & Acceptance - In the past week, seven new drugs or new indications were approved for market launch, 19 new drugs were approved for IND, 35 new INDs were accepted, and 14 new NDAs were accepted [6][29]. - Notable approvals included: - Rongchang Biopharma's injection of Taitasip for rheumatoid arthritis [7]. - Micron Biopharma's PPAR agonist for type 2 diabetes [7]. - Hansoh Pharmaceutical's third-generation EGFR-TKI for acceptance [7]. Domestic New Drug Industry Focus - The report highlights the acceptance of clinical trial applications for BRII-693, a novel lipopeptide antibiotic aimed at treating difficult-to-treat multidrug-resistant Gram-negative bacterial infections [35].